DOCSLIB.ORG

Assessment Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Assessment Report 13 October 2016 EMA/734748/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report SomaKit TOC International non-proprietary name: edotreotide Procedure No. EMEA/H/C/004140/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact An agency of the European Union Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ..................................................................................... 6 1.2. Steps taken for the assessment of the product ........................................................ 7 2. Scientific discussion ................................................................................ 8 2.1. Problem statement ............................................................................................... 8 2.1.1. Disease or condition .......................................................................................... 8 2.1.2. Epidemiology .................................................................................................... 8 2.1.3. Biologic features ............................................................................................... 9 2.1.4. Clinical presentation ........................................................................................ 10 2.1.5. Management ................................................................................................... 10 2.2. Quality aspects .................................................................................................. 13 2.2.1. Introduction.................................................................................................... 13 2.2.2. Active Substance ............................................................................................. 14 2.2.3. Finished Medicinal Product ................................................................................ 17 2.2.4. Discussion on chemical, pharmaceutical and biological aspects.............................. 20 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects ...................... 20 2.2.6. Recommendation(s) for future quality development ............................................. 20 2.3. Non-clinical aspects ............................................................................................ 21 2.3.1. Introduction.................................................................................................... 21 2.3.2. Pharmacology ................................................................................................. 21 2.3.3. Pharmacokinetics ............................................................................................ 24 2.3.4. Toxicology ...................................................................................................... 30 2.3.5. Ecotoxicity/environmental risk assessment ......................................................... 34 2.3.6. Discussion on non-clinical aspects ..................................................................... 35 2.3.7. Conclusion on the non-clinical aspects ............................................................... 37 2.4. Clinical aspects .................................................................................................. 37 2.4.1. Introduction.................................................................................................... 37 2.4.2. Pharmacokinetics ............................................................................................ 37 2.4.3. Pharmacodynamics .......................................................................................... 44 2.4.4. Discussion on clinical pharmacology ................................................................... 48 2.4.5. Conclusions on clinical pharmacology ................................................................. 50 2.5. Clinical efficacy .................................................................................................. 51 2.5.1. Dose response studies ..................................................................................... 51 2.5.2. Main studies ................................................................................................... 52 2.5.3. Discussion on clinical efficacy ............................................................................ 83 2.5.4. Conclusions on the clinical efficacy .................................................................... 87 2.6. Clinical safety .................................................................................................... 87 2.6.1. Discussion on clinical safety .............................................................................. 89 2.6.2. Conclusions on the clinical safety ...................................................................... 91 Assessment report EMA/734748/2016 Page 2/104 2.7. Risk Management Plan ........................................................................................ 92 2.8. Pharmacovigilance ............................................................................................. 93 2.9. Product information ............................................................................................ 93 2.9.1. User consultation ............................................................................................ 93 2.9.2. Additional monitoring ....................................................................................... 93 3. Benefit-Risk Balance ............................................................................. 94 3.1. Conclusions ..................................................................................................... 103 4. Recommendations ............................................................................... 103 Assessment report EMA/734748/2016 Page 3/104 List of abbreviations 68Ga-DOTATATE 68Ga-DOTA- Phe1-Tyr3-octreotide 68Ga-DOTATOC 68Ga-edotreotide or 68Ga-DOTA-Phe1-Tyr3-octreotide 68Ge Germanium-68 Acc diagnostic accuracy CT computed tomography CE CT contrast enhanced computed tomography CTV clinical target volume DOTATOC edotreotide DWI diffusion-weighted imaging EUS endoscopic ultrasonography FDG 18F-fludeoxyglucose FDOPA 6-fluoro-(18F)-L-dihydroxyphenylalanine (or 6-fluoro-(18F)-L-dopa) FSRT fractionated stereotactic radiotherapy FWHM full width half maximum Gd-EOB-DTPA gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid GEP NET gastroenteropancreatic neuroendocrine tumour GTV gross tumour volume i.a. intra-arterial IMRT intensity modulated radiation therapy i.v. intravenous MDCT multidetector computed tomography mRNA messenger ribonucleic acid NET neuroendocrine tumour PET positron emission tomography PET/CT positron emission tomography/computed tomography p.i. post injection PRRT peptide receptor radionuclide therapy PTV planning target volume RECIST Response Evaluation Criteria in Solid Tumours SB skull base Assessment report EMA/734748/2016 Page 4/104 Se sensitivity Sp specificity SPECT single photon emission computed tomography SPECT/CT single photon emission computed tomography/ computed tomography SRPET somatostatin positron emission tomography SRS somatostatin receptor scintigraphy SST somatostatin SSTR(s) somatostatin receptor(s) sstr2 somatostatin receptor subtype 2 SUV standardized uptake value SUVmax maximal standardized uptake value SUVmean mean standardized uptake value SUV T/L standardized uptake value tumour/liver SUV T/S standardized uptake value tumour/spleen T/NTR tumour/non-tumour (target/non-target) ratio wbMRI whole-body magnetic resonance imaging VOI volume of interest Assessment report EMA/734748/2016 Page 5/104 1. Background information on the procedure 1.1. Submission of the dossier The applicant Advanced Accelerator Applications submitted on 8 October 2015 an application for marketing authorisation to the European Medicines Agency (EMA) for SomaKit TOC, through the centralised procedure falling within the Article 3(1) and point 4 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 26 February 2015. SomaKit TOC was designated as an orphan medicinal product EU/3/15/1450 on 19 March 2015 for Diagnosis of gastro-entero-pancreatic neuroendocrine tumours. The applicant applied for the following indication: “This medicinal product is for diagnostic use only. After reconstitution and radiolabelling with 68-Gallium (68Ga) chloride solution, the solution obtained is indicated in adults for the diagnosis and management of somatostatin receptor bearing gastroenteropancreatic neuroendocrine tumours (GEP-NET), including their localisation, characterisation, staging and restaging through positron emission tomography (PET). Gallium (68Ga) edotreotide binds to somatostatin receptors. Tumours which do not bear somatostatin receptors will not be visualised.” Following the CHMP positive opinion on this marketing authorisation, the Committee for Orphan Medicinal Products (COMP) reviewed the designation of SomaKit TOC as an orphan medicinal product in the approved indication. The outcome of the COMP review can be found on the Agency's website: ema.europa.eu/Find medicine/Rare disease designations. The legal basis for this application refers to: Article 10(a)
Load more

Recommended publications
  • Targeting Somatostatin Receptors: Preclinical Evaluation of Novel 18F-Fluoroethyltriazole-Tyr3-Octreotate Analogs for PET
    Journal of Nuclear Medicine, published on August 18, 2011 as doi:10.2967/jnumed.111.088906 Targeting Somatostatin Receptors: Preclinical Evaluation of Novel 18F-Fluoroethyltriazole-Tyr3-Octreotate Analogs for PET Julius Leyton1, Lisa Iddon2, Meg Perumal1, Bard Indrevoll3, Matthias Glaser2, Edward Robins2, Andrew J.T. George4, Alan Cuthbertson3, Sajinder K. Luthra2, and Eric O. Aboagye1 1Comprehensive Cancer Imaging Center at Imperial College, Faculty of Medicine, Imperial College London, London, United Kingdom; 2MDx Discovery (part of GE Healthcare) at Hammersmith Imanet Ltd., Hammersmith Hospital, London, United Kingdom; 3GE Healthcare AS, Oslo, Norway; and 4Section of Immunobiology, Faculty of Medicine, Imperial College London, London, United Kingdom Key Words: somatostatin receptor; octreotide; 18F-fluoroethyl- The incidence and prevalence of gastroenteropancreatic triazole-Tyr3-octreotate; positron emission tomography; and neuroendocrine tumors has been increasing over the past 3 neuroendocrine decades. Because of high densities of somatostatin receptors J Nucl Med 2011; 52:1–8 (sstr)—mainly sstr-2—on the cell surface of these tumors, 111In- DOI: 10.2967/jnumed.111.088906 diethylenetriaminepentaacetic acid-octreotide scintigraphy has become an important part of clinical management. 18F-radio- labeled analogs with suitable pharmacokinetics would permit PET with more rapid clinical protocols. Methods: We compared the affinity in vitro and tissue pharmacokinetics by PET of 5 structurally related 19F/18F-fluoroethyltriazole-Tyr3-octreotate The incidence and prevalence of gastroenteropancreatic (FET-TOCA) analogs: FET-G-polyethylene glycol (PEG)-TOCA, neuroendocrine tumors (GEP-NETs) has increased signifi- FETE-PEG-TOCA, FET-G-TOCA, FETE-TOCA, and FET-bAG- cantly over the past 3 decades (1). The most common site TOCA to the recently described 18F-aluminum fluoride NOTA- of primary GEP-NETs is the gastrointestinal tract (60%).
    [Show full text]
  • Alshaer Danah Mahdi 2020.Pdf (14.70Mb)
    Synthesis and physiochemical characterization of new siderophore- inspired peptide-chelators with 1- hydroxypridine-2-one (1,2-HOPO) Thesis Submitted in fulfilment of the requirements for the degree of Doctor of Philosophy by Danah Mahdi AlShaer 2020 Supervisor: Prof. Beatriz Garcia de la Torre Co-supervisor: Prof. Fernando Albericio Synthesis and physiochemical characterization of new siderophore-inspired peptide• chelators with 1-hydrnxypridine-2-one (1,2-JB[OPO) 217078895 Danah Mahdi AllSlh.aer A thesis submitted to the School of Health Sciences, College of Health Sciences, University of KwaZulu-Natal, Westville, for the degree of Doctor of Philosophy by research in Pharmaceutical Chemistry. This is the thesis in which the chapters are written as a set of discrete research publications that have followed each journal's format with an overall introduction and final summary. These chapters have been published in internationally recognized, peer-reviewed journals. This is to certify that the contents of this thesis are the original research work of Mrs Danah Mahdi AllSllnaer, carried out under our supervision at the Peptide Sciences Laboratory, Westville campus, University of KwaZulu-Natal, Durban, South Africa. Supervisor: --"-:I-----::... Date: gth December 2020 Date: 8th December 2020 As the candidate's supervisors we agree to the submission of this thesis Table of Contents Abstract……………..…………………………………………………………………..……1 Declaration 1: Plagiarism.……………………………………………………….…………..2 Declaration 2: Publications ….………………………………………………….…...….…..3 Acknowledgment………………………………………..………………...…………….…..5 Aim and objectives……….….……………………………………………………………...6 Chapter 1: (Introduction) Hydroxamate Siderophores: Natural Occurrence, Chemical Synthesis, Iron Binding Affinity and Use as Trojan Horses Against ………..……….. 7 Reprint………………………………………………………………………………………8 Chapter 2: Solid-phase synthesis of peptides containing 1-Hydroxypyridine-2-one (1,2-HOPO) …………………………………………………….……………………….
    [Show full text]
  • Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
    International Journal of Molecular Sciences Review Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future Anna Kathrin Stueven 1, Antonin Kayser 1, Christoph Wetz 2, Holger Amthauer 2, Alexander Wree 1, Frank Tacke 1, Bertram Wiedenmann 1, Christoph Roderburg 1,* and Henning Jann 1 1 Charité, Campus Virchow Klinikum and Charité, Campus Mitte, Department of Hepatology and Gastroenterology, Universitätsmedizin Berlin, 10117 Berlin, Germany; [email protected] (A.K.S.); [email protected] (A.K.); [email protected] (A.W.); [email protected] (F.T.); [email protected] (B.W.); [email protected] (H.J.) 2 Charité, Campus Virchow Klinikum and Charité, Campus Mitte, Department of Nuclear Medicine, Universitätsmedizin Berlin, 10117 Berlin, Germany; [email protected] (C.W.); [email protected] (H.A.) * Correspondence: [email protected]; Tel.: +49-30-450-553022 Received: 3 May 2019; Accepted: 19 June 2019; Published: 22 June 2019 Abstract: In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no longer available. Prognosis and survival of patients with NETs are determined by the location of the primary lesion, biochemical functional status, differentiation, initial staging, and response to treatment. Somatostatin analogue (SSA) therapy has been a mainstay of antisecretory therapy in functioning neuroendocrine tumors, which cause various clinical symptoms depending on hormonal hypersecretion. Beyond symptomatic management, recent research demonstrates that SSAs exert antiproliferative effects and inhibit tumor growth via the somatostatin receptor 2 (SSTR2).
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Downloaded from Bioscientifica.Com at 09/23/2021 09:50:19AM Via Free Access
    5 181 S W J Lamberts and Octreotide 181:5 R173–R183 Review L J Hofland ANNIVERSARY REVIEW Octreotide, 40 years later Correspondence should be addressed Steven W J Lamberts and Leo J Hofland to S W J Lamberts Division of Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands Email [email protected] Abstract Octreotide remains 40 years after its development a drug, which is commonly used in the treatment of acromegaly and GEP-NETs. Very little innovation that competes with this drug occurred over this period. This review discusses several aspects of 40 years of clinical use of octreotide, including the application of radiolabeled forms of the peptide. European Journal of Endocrinology (2019) 181, R173–R183 Introduction A peptide inhibiting the release of growth hormone initial enthusiasm for its clinical use. From 1978 on, a (GH) was accidentally detected in the hypothalamus of number of drug companies started programs to synthesize rats during studies of the distribution of GH-releasing long-acting somatostatin analogs. factor (1). This peptide, called somatostatin, is a peptide Octreotide (SMS 201-995) was one of the first hormone that plays an inhibitory role in the regulation biologically stable somatostatin analogs to be synthesized of multiple physiological functions, including pituitary, (8): it has a much longer half-life in the human circulation European Journal of Endocrinology pancreatic and gastrointestinal hormone secretion (2, 3). than somatostatin and binds with a high affinity to Somatostatin exerts its biological effects by interaction SST2 (9). The structure of natural somatostatin and with specific somatostatin receptors (SSTs) expressed on octreotide is shown in Fig.
    [Show full text]
  • Multi-Discipline Review(S)
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210828Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA/BLA Multi-Disciplinary Review and Evaluation (NDA 210828) 505(b)(2) (Ga-68-DOTATOC) NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NME & 505 (b)(2) Application Number(s) NDA 210828 Priority or Standard Standard Submit Date(s) May 23, 2018 Received Date(s) May 23, 2018 PDUFA Goal Date August 23, 2019 Division/Office Office of Drug Evaluation IV/Division of Medical Imaging Products (DMIP/ODEIV) Review Completion Date TBD Established/Proper Name Ga-68-DOTATOC injection (Proposed) Trade Name Not applicable Pharmacologic Class Radioactive diagnostic agent Code name IC2000 Applicant University of Iowa Health Care/P.E.T. Imaging Center Dosage Form Injection: Clear, colorless solution containing 18.5 to 148 MBq/mL (0.5 to 4 mCi/mL) of Ga-68-DOTATOC injection at end of synthesis (EOS) (approximately 14 mL volume) in a 30 mL multiple-dose vial. Applicant proposed Dosing For adults: 148 MBq (4 mCi); for pediatric patients: 1.59 Regimen MBq/kg (0.043 mCi/kg) with a range of 11.1 MBq (0.3 mCi) to 111 MBq (3 mCi) Applicant Proposed For localization of somatostatin receptor positive (b) (4) Indication(s)/Population(s) neuroendocrine tumors (NETs) in (b) (4) adult and pediatric patients. Applicant Proposed Indicated for use with positron emission tomography (PET) for SNOMED CT Indication localization of somatostatin receptor positive neuroendocrine (b) (4) Disease Term for Each tumors (NETs) in adult and pediatric (b) (4) Proposed Indication patients.
    [Show full text]
  • Overview of Results of Peptide Receptor Radionuclide Therapy with 3 Radiolabeled Somatostatin Analogs
    Overview of Results of Peptide Receptor Radionuclide Therapy with 3 Radiolabeled Somatostatin Analogs Dik J. Kwekkeboom, MD1; Jan Mueller-Brand, MD2; Giovanni Paganelli, MD3; Lowell B. Anthony, MD4; Stanislas Pauwels, MD5; Larry K. Kvols, MD6; Thomas M. O’Dorisio, MD7; Roelf Valkema, MD1; Lisa Bodei, MD3; Marco Chinol, PhD3; Helmut R. Maecke, PhD2; and Eric P. Krenning, MD1 1Department of Nuclear Medicine, Erasmus Medical Center, University Hospital Rotterdam, Rotterdam, The Netherlands; 2Department of Nuclear Medicine, University Hospital Basel, Basel, Switzerland; 3Department of Nuclear Medicine, European Institute of Oncology, Milan, Italy; 4Division of Hematology and Oncology, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana; 5Department of Nuclear Medicine, Universitaire Catholique Louvain, Brussels, Belgium; 6Lee Moffitt Cancer Center, University of South Florida, Tampa, Florida; and 7Division of Endocrinology, Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa Key Words: somatostatin; somatostatin receptor; radionuclide A new treatment modality for inoperable or metastasized gas- therapy; gastroenteropancreatic tumors troenteropancreatic tumors is the use of radiolabeled soma- J Nucl Med 2005; 46:62S–66S tostatin analogs. Initial studies with high doses of [111In-diethyl- enetriaminepentaacetic acid (DTPA)0]octreotide in patients with metastasized neuroendocrine tumors were encouraging, al- though partial remissions were uncommon. Another radiola- beled somatostatin analog that is used for peptide receptor Neuroendocrine gastroenteropancreatic (GEP) tumors, radionuclide therapy (PRRT) is [90Y-1,4,7,10-tetraazacyclodode- which comprise pancreatic islet cell tumors, nonfunctioning -cane-N,NЈ,NЉ,Nٞ-tetraacetic acid (DOTA)0,Tyr3]octreotide. Vari- neuroendocrine pancreatic tumors, and carcinoids, are usu ous phase 1 and phase 2 PRRT trials have been performed with ally slow growing.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Use of DOTATATE PET/CT Scan in the Diagnosis and Staging Of
    WJOESWJOES DOTATATE10.5005/jp-journals-10002-1231 PET/CT in Thymic Carcinoid CASE REPORT Use of DOTATATE PET/CT Scan in the Diagnosis and Staging of Thymic Atypical Carcinoid Tumor in a Patient with Secondary ACTH-dependent Cushing Syndrome: Look Twice and Cut Once 1John Agzarian, 2Hisham Quandeel, 3Irina Bancos, 4Geoffrey B Johnson, 5Stephen C Scharf, 6Geoffrey B Thompson 7Joanne Yi, 8Xiaotun Zhang, 9K Robert Shen ABSTRACT Keywords: DOTATATE, Mediastinal, Positron emission tomog- raphy, Thymic carcinoid. Neuroendocrine thymic tumors represent the least common type of primary thymic tumor with a prevalence of 2 to 5%. We How to cite this article: Agzarian J, Quandeel H, Bancos I, present a case of locally advanced thymic atypical carcinoid Johnson GB, Scharf SC, Thompson GB, Yi J, Zhang X, Shen KR. tumor diagnosed incidentally while investigating progressive Use of DOTATATE PET/CT Scan in the Diagnosis and Staging of Thymic Atypical Carcinoid Tumor in a Patient with Second- Cushing syndrome. Computed tomography (CT) scan demon- ary ACTH-dependent Cushing Syndrome: Look Twice and Cut strated a large 2.9 cm exophytic thyroid nodule and a 2.0 cm Once. World J Endoc Surg 2018;10(2):127-133. anterior mediastinal mass. Biopsy of the thyroid nodule demon- strated benign thyroid tissue, and octreotide scan revealed avid Source of support: Nil uptake in the right thyroid lobe with minimal uptake in the thymic Conflict of interest: None tumor. 68Gallium-1,4,7,10-tetraazacyclododecane-N,N′,N″N′″- tetraacetic acid-D-Phe1,Tyr 3-octreotate (Ga-68 DOTATATE) positron emission tomography (PET)/CT scan showed intense INTRODUCTION uptake in the thyroid gland followed by a moderate amount of activity in the anterior mediastinal mass.
    [Show full text]
  • 2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
    2016 Medicines in Development for Rare Diseases A LIST OF ORPHAN DRUGS IN THE PIPELINE Autoimmune Diseases Product Name Sponsor Official FDA Designation* Development Status Actemra® Genentech treatment of systemic sclerosis Phase III tocilizumab South San Francisco, CA www.gene.com Adempas® Bayer HealthCare Pharmaceuticals treatment of systemic sclerosis Phase II riociguat Whippany, NJ www.pharma.bayer.com ARA 290 Araim Pharmaceuticals treatment of neuropathic pain in patients Phase II Tarrytown, NY with sarcoidosis www.ariampharma.com ARG201 arGentis Pharmaceuticals treatment of diffuse systemic sclerosis Phase II (type 1 native bovine skin Collierville, TN www.argentisrx.com collagen) BYM338 Novartis Pharmaceuticals treatment of inclusion body myositis Phase III (bimagrumab) East Hanover, NJ www.novartis.com CCX168 ChemoCentryx treatment of anti-neutrophil cytoplasmic Phase II (5a receptor antagonist) Mountain View, CA auto-antibodies associated vasculitides www.chemocentryx.com (granulomatosis with polyangitis or Wegener's granulomatosis), microscopic polyangitis, and Churg-Strauss syndrome * This designation is issued by the FDA's Office of Orphan Products Development while the drug is still in development. The designation makes the sponsor of the drug eligible for entitlements under the Orphan Drug Act of 1983. The entitlements include seven years of marketing exclusivity following FDA approval of the drug for the designated use. Medicines in Development: Rare Diseases | 2016 1 Autoimmune Diseases Product Name Sponsor Official FDA
    [Show full text]
  • First Patient in Phase III Clinical Trial COMPETE with N.C.A.177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET
    Garching, Germany, April 18, 2017 First Patient in Phase III Clinical Trial COMPETE with n.c.a.177Lu-Edotreotide (Solucin®) in Cancer Patients with GEP-NET Solucin® (n.c.a. 177Lu-Edotreotide) to be shown as a highly precise and effective Targeted Radionuclide Therapy Agent Promising data of Solucin® expected to be confirmed in phase III clinical trial COMPETE Solucin® to demonstrate prolonged PFS compared to mTOR inhibitor Everolimus ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, today announced the enrollment of the first patient recruited in the COMPETE study, an international pivotal multi-center phase III clinical trial evaluating the efficacy and safety of n.c.a.177Lu-Edotreotide (Solucin®) compared to Everolimus in patients with inoperable, progressive, somatostatin-receptor positive neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET). The primary endpoint is progression-free survival (PFS). With Solucin® a retrospective phase II efficacy and safety study of Targeted Radionuclide Therapy in patients with advanced neuroendocrine tumors (NET) with encouraging results has been performed. The results suggest and demonstrate a significant benefit, a substantially improved progression-free survival (PFS).1 Therefore Solucin® received an Orphan Designation (EMA/OD/196/13). Due to these favorable data and the long-term experience with n.c.a. 177Lu-Edotreotide under compassionate use, ITM is positive to verify the results in the clinical phase III trial, known as COMPETE. The study will be conducted predominantly in Europe, North America, South Africa and Australia. The first patient has been enrolled and will be treated in Australia. Solucin® is injected into the patient´s body where it specifically accumulates at the tumor.
    [Show full text]
  • Page 1 of 19 RSC Advances
    RSC Advances This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication. Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This Accepted Manuscript will be replaced by the edited, formatted and paginated article as soon as this is available. You can find more information about Accepted Manuscripts in the Information for Authors. Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. www.rsc.org/advances Page 1 of 19 RSC Advances A greener approach toward gadolinium-based contrast agents Thais P. Gazzi, Luiz A. Basso, Diógenes S. Santos* and Pablo Machado* Instituto Nacional de Ciência e Tecnologia em Tuberculose, Centro de Pesquisas em Biologia Molecular e Funcional, Programa de Pós-Graduação em Biologia Celular e Molecular, Pontifícia Universidade Católica do Rio Grande do Sul, 90619-900, Porto Alegre, RS, Brazil Manuscript Accepted Advances RSC *Corresponding authors. Phone/Fax: +55 51 3320 3629 E-mail address: [email protected] (D.S. Santos); [email protected] (P. Machado) RSC Advances Page 2 of 19 Graphical Abstract Manuscript Abstract Gadolinium-based contrast agents are widely used to enhance the contrast of images in magnetic resonance imaging procedures.
    [Show full text]